Head-to-head comparison
| Property | MOTS-c | SS-31 |
|---|---|---|
| Category | Longevity | Longevity |
| Legal Status | Research Only | Research Only |
| Primary Route | subcutaneous | subcutaneous |
| Half-life | ~4 hours (estimated) | ~4 hours |
| Mol. Weight | 2,174.54 Da | 640.75 Da |
| Side Effects | Injection site reactions, Mild GI discomfort, Fatigue (transient) | Injection site reactions, Headache, Dizziness |
Key differences
- Mechanism: MOTS-c activates AMPK to regulate glucose metabolism, insulin sensitivity, and fatty acid oxidation; SS-31 binds cardiolipin on the inner mitochondrial membrane to stabilize electron transport chain function and reduce ROS production.
- Origin: MOTS-c is an endogenous peptide encoded in the mitochondrial genome (12S rRNA gene); SS-31 is a wholly synthetic peptide designed by Hazel Szeto at Weill Cornell Medical College.
- Clinical development: SS-31 has advanced clinical trials including Phase III for Barth syndrome (TAZPOWER), Phase II for heart failure (PROGRESS-HF), and Phase II for macular degeneration (ReCLAIM); MOTS-c clinical trials are in early stages.
- Dosing: MOTS-c is dosed at 5-10 mg subcutaneously 3-5x weekly; SS-31 clinical trial doses range from 4-40 mg daily subcutaneously or intravenously.
- Mitochondrial targeting: SS-31 physically concentrates 1000-5000x in mitochondria relative to cytoplasm due to its aromatic-cationic structure; MOTS-c acts primarily through AMPK signaling and nuclear translocation under metabolic stress.
- Side effects: SS-31 clinical trials report injection site reactions, headache, dizziness, and nausea; MOTS-c reports are limited to injection site reactions, mild GI discomfort, and transient fatigue from community use.
- Legal status: SS-31 is an investigational drug with orphan drug designation for Barth syndrome (Stealth BioTherapeutics); MOTS-c is a research-only peptide with limited regulatory attention.
The verdict
SS-31 is clinically more advanced than MOTS-c, with Phase II and III trial data across multiple indications including Barth syndrome, heart failure, and macular degeneration. MOTS-c has a distinct metabolic regulatory profile centered on AMPK activation rather than direct mitochondrial membrane stabilization. The two peptides address different aspects of mitochondrial dysfunction: SS-31 optimizes electron transport and ATP synthesis at the membrane level, while MOTS-c coordinates broader cellular energy metabolism through AMPK signaling. Neither approach is a substitute for the other.
Frequently asked questions
Because they target different aspects of mitochondrial biology — MOTS-c through AMPK-mediated metabolic regulation and SS-31 through cardiolipin stabilization of the electron transport chain — they are sometimes listed as complementary in longevity protocols. No studies have evaluated this combination.
SS-31 (elamipretide) has substantially more clinical evidence, including Phase III data in Barth syndrome (TAZPOWER), Phase II data in heart failure (PROGRESS-HF), and Phase II data in macular degeneration (ReCLAIM). MOTS-c clinical trials are still in early stages, with most evidence coming from preclinical animal studies.
SS-31 has an alternating aromatic-cationic structure that causes it to concentrate 1000-5000x in mitochondria relative to cytoplasm, physically embedding in the inner mitochondrial membrane. MOTS-c does not physically concentrate in mitochondria; it signals through AMPK in the cytoplasm and translocates to the nucleus under metabolic stress.
SS-31 (elamipretide) is an investigational drug developed by Stealth BioTherapeutics and is not yet FDA-approved. It has orphan drug designation for Barth syndrome. It is not widely available from standard research peptide suppliers, making it less accessible than MOTS-c for non-clinical research.
MOTS-c has been described as an exercise mimetic because circulating levels increase during exercise and it activates some of the same AMPK pathways that exercise does. However, it does not replicate the full spectrum of exercise benefits including cardiovascular conditioning, neuromuscular adaptation, and bone loading. It should not be considered a replacement for physical activity.